-The Hoot The media welcomed the UID's promise of giving an identity to those outside the system, but has failed to track its failure to do so. On January 1, the Indian government announced roll out of its ambitious cash transfer scheme in 20 districts of the country based on unique identification (UID), also called Aadhaar. The media, while presenting the pros and cons of cash transfer, also mentioned that...
More »SEARCH RESULT
Total Matching Records found : 97
Kudankulam on shaky legal ground-D Nagasaila and V Suresh
-The Hindu Violations of Coastal Regulation Zone and Environmental Impact Assessment notifications make official claims questionable The debate over nuclear energy will go on, but the issue with the Kudankulam Nuclear Power Plant (KKNPP) is one of the several illegalities on which it is founded. In 1988, India inked the Koodankulam Nuclear Power Plant deal with the former Soviet Union. Two key elements in it were: the highly dangerous and toxic “Spent Nuclear...
More »IPAB dismisses Bayer's stay plea in Nexavar case
-The Economic Times MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory licence issued to Hyderabad-based drugmaker Natco. The Compulsory licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at...
More »Patients lose out to patents & profits -Deepa Kurup
-The Hindu A 2012 WHO study ranks India third — behind Myanmar and Bangladesh — among countries that fail to provide health cover to people. A 2011 study reported in The Lancet on ‘Healthcare and equity’ confirms this: every year, at least 39 million people here fall into poverty due to private out-of-pocket health expenditure. A vast majority of Indians do not have access to healthcare or essential drugs. By the...
More »Natco targets drugs ripe for compulsory licensing-Viswanath Pilla
-Live Mint Natco Pharma Ltd, which has started selling a generic version of Bayer AG’s patented cancer treatment Nexavar in India at a fraction of the price charged by the German firm, plans to use the so-called compulsory licensing route to try and win the right to copy more patented drugs, said vice-chairman and chief executive officer Rajeev Nannapaneni. The Hyderabad-based company has already identified the patented drugs for which it will...
More »
